Genzyme Executive VP-Legal And Corporate Development Peter Wirth: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)
Wirth talks about Genzyme’s contentious acquisition of AnorMED and current shareholder objections to the company’s bid to acquire clofarabine partner Bioenvision.